Relative Bioavailability of a Fentanyl Patch

NCT00857753 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-03-29

No results posted yet for this study

Summary

Tohe purpose of this study is to demonstrate the bioequivalence of a fentanyl patch transdermal delivery system.

Conditions

Interventions

DRUG

Fentanyl patch 25 ug/nr Sandoz

DRUG

Duragesic

Sponsors & Collaborators

Principal Investigators

  • Darin B. Brimhall, D.O. · Novum Pharmaceutical Research Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2006-10-31
Completion
2006-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857753 on ClinicalTrials.gov